dromlakhani No preference among oral contraceptive formulations for hirsutism
STEP 1 — Gather Information
Confirm patient-important hirsutism (Ferriman–Gallwey score above population 95th percentile, distress prompting further treatment), assess fertility desire, menstrual regularity, and signs of endocrine disorder (oligoovulation, virilization, etc.). Document current cosmetic measures (shaving, plucking, waxing) and their inadequacy.
STEP 2 — Rule In / Rule Out
If patient-important hirsutism persists despite cosmetic measures and the woman is not seeking fertility → proceed to OC therapy.
If hirsutism is mild, no endocrine disorder evident, and the woman prefers non‑pharmacologic approach → consider direct hair removal instead (patient preference).
STEP 3 — Classify or Stratify
For women proceeding to OC therapy, no stratification by formulation is needed; all combined estrogen–progestin OCs are considered equally effective for hirsutism with low side‑effect risk.
STEP 4 — Decide
Start any combined estrogen–progestin oral contraceptive (e.g., ethinyl estradiol 20–35 mcg with any progestin) as initial therapy. Reassess hirsutism after ≥6 months; if insufficient improvement, add an antiandrogen.
Clinical Guardrails / Mimics / Pitfalls
Do not use antiandrogen monotherapy without reliable contraception (teratogenic risk). Avoid insulin‑lowering drugs for hirsutism alone. In women with VTE risk factors (obesity, age > 39 years), choose the lowest effective EE dose (usually 20 mcg) and a low‑risk progestin. Do not assume one OC formulation is superior; switching OC brands without clinical reason is not indicated. Monitor for VTE, hypertension, and mood changes.
Concrete Clinical Example
A 28‑year‑old woman presents with FG score 12, facial hair causing distress, regular menses, no desire for pregnancy, and inadequate response to shaving. She has no signs of endocrine disorder. Start any combined OC (e.g., EE 20 mcg + levonorgestrel 0.15 mg). After 6 months, if hair growth remains problematic, add spironolactone 100 mg BID.
Source: Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-00241